medigraphic.com
ISSN 1995-9494 (Electronic)
Revista del Hospital Clínico Quirúrgico "Arnaldo Milián Castro"

2017, Number 2

<< Back Next >>

Acta Med Cent 2017; 11 (2)

Enfermedad hepática grasa no alcohólica. Algunas consideraciones diagnósticas

Suárez GM, López MVM, Eirin RJM, González GEL, Medina GY, Díaz OSE

Language: Spanish
References: 20
Page: 10-18
PDF size: 206.53 Kb.


ABSTRACT

Introduction: non-alcoholic fatty liver is the third cause of chronic liver disease in the world and is associated with obesity, diabetes mellitus type 2 and hyperlipidemia, among others. Objective: to describe some clinical, biochemical, echographic and histological aspects in a group of patients with liver disease by non-alcoholic fat deposition. Method: a descriptive cross-sectional study was carried out from September 2014 to February 2016, the sample was 41 patients who underwent an analytical evaluation and the histological and hepatic ultrasound findings were compared. Results: the sex most affected was female (33, 80,5%); the most altered biochemical parameters were alaninoaminotransferase (34, 82,9%) and glycemia (33, 80,5%); 20 of 26 patients older than 45 years presented steatohepatitis with fibrosis and 22 of the total severe steatosis according to ultrasonography (53,6%). Conclusions: female gender and age over 45 years predominated, the alaninoaminotransferase and the glycemia were the biochemical parameters that showed the highest elevation, the most relevant ultrasonographic finding was the severe hepatic steatosis and the existence of steatohepatitis with fibrosis prevailed since the anatomopathological point of view.


REFERENCES

  1. Ascha MS, Hanouneh IA, López R, Tamimi TA, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology [Internet]. 2010 [citado 17 Mar 2016];51(6):1972-8. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/20209604

  2. Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology [Internet]. 2010 [citado 17 Mar 2016];51(1):121-9. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/19827166

  3. Pérez Lorenzo M, Duarte Castillo N, Montero González T, Franco Estrada S, Winograd Lay R, Brizuela Quintanilla RA. Prevalencia del hígado graso no alcohólico en muestras de biopsias hepáticas. Rev Cubana Med Milit [Internet]. 2006 [citado 17 Mar 2016];35(4):[aprox. 7 p.]. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0138-65572006000400006&lng=es&nrm=iso&tlng=es

  4. Ratziu V, Charlotte F, Bernhardt C, Giral P, Halbron M, Lenaour G, et al. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology [Internet]. 2010 [citado 17 Mar 2016];51(2):445-453. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/19877169

  5. Valenzuela C, Aguirre C, Castillo V, Ronco AM, Llanos M. Participación del sistema endocanabinoide en el desarrollo de obesidad. Rev Méd Chile [Internet]. 2010 [citado 17 Mar 2016];138(5):621-629. Disponible en: http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872010000500014&lng=en&nrm=iso&tlng=en

  6. Graham ES, Angel CE, Schwarcz LE, Dunbar PR, Glass M. Detailed characterisation of CB2 receptor protein expression in peripheral blood immune cells from healthy human volunteers using flow cytometry. Int J Immunopathol Pharmacol [Internet]. 2010 [citado 17 Mar 2016];23(1):25-34. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/20377992

  7. Méndez-Sánchez N, González V, King-Martínez AC, Sánchez H, Uribe M. Plasma leptin and the cholesterol saturation of bile are correlated in obese women after weight loss. J Nutr [Internet]. 2002 [citado 7 May 2016];132(8):2195-8. Disponible en: http://jn.nutrition.org/content/132/8/2195.full.pdf

  8. Louvet A, Teixeira-Clerc F, Chobert MN, Deveaux V, Pavoine C, Zimmer A, et al. Cannabinoid CB2 receptors protects against alcoholic liver disease by regulating Kupffer cell polarization in mice. Hepatology [Internet]. 2011 [citado 17 Mar 2016];54(4):1217-26. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/21735467

  9. Callén L, Moreno E, Barroso-Chinea P, Moreno-Delgado D, Cortés A, Mallol J, et al. Cannabinoid receptors CB1 and CB2 form functional heteromers in brain. J Biol Chem [Internet]. 2012 [citado 17 Mar 2016];287(25):20851-65. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/22532560

  10. 10.Liangpunsakul S, Chalasani N. What should we recommend to our patients with NAFLD regarding alcohol use? Am J Gastroenterol [Internet]. 2012 [citado 17 Mar 2016];107(7):976-978. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/22764020

  11. 11.Crespo García J, Arias Loste MT. Esteatohepatitis no alcohólica [Internet]. En: Farreras Valenti P, Rozman C. Farreras-Rozman Medicina Interna. España: Elsevier; 2012. p. 335-340 [citado 17 Mar 2016]. Disponible en: https://www.clinicalkey.es/#!/content/book/3-s2.0-B9788490229965000405

  12. 12.Tam J, Cinar R, Liu J, Godlewski G, Wesley D, Jourdan T, et al. Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance. Cell Metab [Internet]. 2012 [citado 17 Mar 2016];16(2):167-79. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/22841573

  13. 13.Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology [Internet]. 2010 [citado 17 Mar 2016];51(2):679-89.Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/20041406

  14. 14.Rakoski MO, Singal AG, Rogers MA, Conjeevaram H. Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther [Internet]. 2012 [citado 17 Mar 2016];32(10):1211-21. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/20955440

  15. 15.Yilmaz Y. NAFLD in the absence of metabolic syndrome: different epidemiology, pathogenetic mechanisms, risk factors for disease progression? Semin Liver Dis [Internet]. 2014 [citado 17 Mar 2016];32(1):14-21. Disponible en: https://www.researchgate.net/publication/221896525_NAFLD_in_the_Absence_of_Metabolic_Syndrome_Different_Epidemiology_Pathogenetic_Mechanisms_Risk_Factors_for_Disease_Progression

  16. 16.Liechti F, Dufour JF. Treatment of NASH with ursodeoxycholic acid: cons. Clin Res Hepatol Gastroenterol [Internet]. 2012 [citado 17 Mar 2016];36 Suppl 1:S46-52. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/23141894

  17. 17.Ratziu V. Treatment of NASH with ursodeoxycholic acid: pro. Clin Res Hepatol Gastroenterol [Internet]. 2012 [citado 17 Mar 2016];36 Suppl 1:S41-5. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/23141893

  18. 18.Caporaso N, Morisco F, Camera S, Graziani G, Donnarumma L, Ritieni A. Dietary approach in the prevention and treatment of NAFLD. Front Biosci (Landmark Ed) [Internet]. 2014 [citado 17 Mar 2016];17:2259-68. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/22652776

  19. 19.Di Rosa M, Malaguarnera L. Genetic variants in candidate genes influencing NAFLD progression. J Mol Med (Berl) [Internet]. 2012 [citado 17 Mar 2016];90(2):105-118. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/21894552

  20. 20.Kim MS, Kung S, Grewal T, Roufogalis BD. Methodologies for investigating natural medicines for the treatment of nonalcoholic fatty liver disease (NAFLD). Curr Pharm Biotechnol [Internet]. 2012 [citado 17 Mar 2016];13(2):278-291. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/21470125




2020     |     www.medigraphic.com